OncoMatch/Clinical Trials/NCT06564623
Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)
Is NCT06564623 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)] and Durvalumab for biliary tract cancers.
Treatment: mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)] · Durvalumab · Tremelimumab — The purpose of this study is to evaluate the safety and the immune response of personalized mutant peptide vaccine with poly-ICLC adjuvant (mBTCvax) in combination with durvalumab and tremelimumab following front-line treatment in patients with advanced stage BTC.
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: gemcitabine (gemcitabine)
previously treated with gemcitabine
Must have received: platinum-based chemotherapy (cisplatin)
previously treated with cisplatin
Must have received: anti-PD-1 therapy
previously treated with anti-PD(L)1 therapy
Lab requirements
Blood counts
adequate organ and marrow function defined by study-specified laboratory tests
Kidney function
adequate organ and marrow function defined by study-specified laboratory tests
Liver function
adequate organ and marrow function defined by study-specified laboratory tests
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- SKCCC Johns Hopkins Medical Institution · Baltimore, Maryland
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify